View Future GrowthXIIlabLtd 過去の業績過去 基準チェック /06XIIlabLtdは1.3%の年平均成長率で業績を伸ばしているが、Software業界はgrowingで7.9%毎年増加している。売上は成長しており、年平均4.5%の割合である。主要情報1.31%収益成長率3.23%EPS成長率Software 業界の成長14.56%収益成長率4.53%株主資本利益率-12.41%ネット・マージン-30.37%次回の業績アップデート28 May 2026最近の業績更新お知らせ • May 15XIIlab Co.,Ltd to Report Q1, 2026 Results on May 28, 2026XIIlab Co.,Ltd announced that they will report Q1, 2026 results at 2:00 PM, Korea Standard Time on May 28, 2026Reported Earnings • Mar 20Full year 2024 earnings released: ₩851 loss per share (vs ₩1,063 loss in FY 2023)Full year 2024 results: ₩851 loss per share (improved from ₩1,063 loss in FY 2023). Revenue: ₩9.09b (up 148% from FY 2023). Net loss: ₩5.19b (loss narrowed 20% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.Reported Earnings • Aug 17Second quarter 2024 earnings released: ₩307 loss per share (vs ₩268 loss in 2Q 2023)Second quarter 2024 results: ₩307 loss per share (further deteriorated from ₩268 loss in 2Q 2023). Revenue: ₩348.2m (up 3.2% from 2Q 2023). Net loss: ₩1.87b (loss widened 15% from 2Q 2023).Reported Earnings • Mar 22Full year 2023 earnings released: ₩1,063 loss per share (vs ₩754 loss in FY 2022)Full year 2023 results: ₩1,063 loss per share (further deteriorated from ₩754 loss in FY 2022). Revenue: ₩3.66b (down 63% from FY 2022). Net loss: ₩6.46b (loss widened 42% from FY 2022).すべての更新を表示Recent updatesお知らせ • May 15XIIlab Co.,Ltd to Report Q1, 2026 Results on May 28, 2026XIIlab Co.,Ltd announced that they will report Q1, 2026 results at 2:00 PM, Korea Standard Time on May 28, 2026New Risk • Apr 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩64.6b market cap, or US$43.9m).分析記事 • Apr 18We Think XIIlabLtd (KOSDAQ:189330) Can Easily Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...お知らせ • Feb 13XIIlab Co.,Ltd, Annual General Meeting, Mar 30, 2026XIIlab Co.,Ltd, Annual General Meeting, Mar 30, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 513, yeongdong-daero, gangnam-gu, seoul South Korea分析記事 • Jan 02Here's Why We're Not At All Concerned With XIIlabLtd's (KOSDAQ:189330) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...New Risk • Aug 30New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 54% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 9.4% per year over the past 5 years. Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩48.4b market cap, or US$34.9m).お知らせ • Aug 16XIIlab Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 36.772394 billion.XIIlab Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 36.772394 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,050,068 Price\Range: KRW 5800 Discount Per Security: KRW 104.4 Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,290,000 Price\Range: KRW 5800 Discount Per Security: KRW 104.4 Transaction Features: Rights OfferingNew Risk • Jul 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩49.2b market cap, or US$36.4m).New Risk • May 22New major risk - Revenue and earnings growthEarnings have declined by 17% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩40.7b market cap, or US$29.5m).お知らせ • May 15XIIlab Co.,Ltd has filed a Follow-on Equity Offering in the amount of KRW 17.8647 billion.XIIlab Co.,Ltd has filed a Follow-on Equity Offering in the amount of KRW 17.8647 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,290,000 Price\Range: KRW 5430 Discount Per Security: KRW 97.74 Transaction Features: Rights OfferingReported Earnings • Mar 20Full year 2024 earnings released: ₩851 loss per share (vs ₩1,063 loss in FY 2023)Full year 2024 results: ₩851 loss per share (improved from ₩1,063 loss in FY 2023). Revenue: ₩9.09b (up 148% from FY 2023). Net loss: ₩5.19b (loss narrowed 20% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 25XIIlab Co.,Ltd, Annual General Meeting, Mar 26, 2025XIIlab Co.,Ltd, Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 513, yeongdong-daero, gangnam-gu, seoul South Korea分析記事 • Dec 05We Think XIIlabLtd (KOSDAQ:189330) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Reported Earnings • Aug 17Second quarter 2024 earnings released: ₩307 loss per share (vs ₩268 loss in 2Q 2023)Second quarter 2024 results: ₩307 loss per share (further deteriorated from ₩268 loss in 2Q 2023). Revenue: ₩348.2m (up 3.2% from 2Q 2023). Net loss: ₩1.87b (loss widened 15% from 2Q 2023).分析記事 • Jul 26Is XIIlabLtd (KOSDAQ:189330) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Reported Earnings • Mar 22Full year 2023 earnings released: ₩1,063 loss per share (vs ₩754 loss in FY 2022)Full year 2023 results: ₩1,063 loss per share (further deteriorated from ₩754 loss in FY 2022). Revenue: ₩3.66b (down 63% from FY 2022). Net loss: ₩6.46b (loss widened 42% from FY 2022).お知らせ • Mar 20Xiilab Unveils Cutting-Edge AI Technologies At NVIDIA GTCXiilab announced its participation in the global AI conference, NVIDIA GTC, held in San Jose, California, USA, and online from March 18th to 21st, 2024. Xiilab plans to showcase its AI technology at GTC through three main products: AI video analysis service ('VidiGo'), synthetic data generation solution ('X-GEN'), and GPU orchestration solution. The first product, 'VidiGo,' is a cloud-based AI video analysis service that accurately summarizes the core contents of a video without watching it. It can also quickly search for desired video scenes. Users can easily make a database of characters, objects, and dialogues in the video, which significantly improves work efficiency in the media industry. The second product, 'X-GEN,' is a solution for generating synthetic data for AI model training. Especially in areas like disaster response or defense, there is a shortage of data for AI training. X-GEN can provide synthetic data which can replace real data in such rare conditions, even maximizing AI training performance. Xiilab has been applying 'X-GEN' in the digital twin field using the NVIDIA Omniverse. platform, which provides 3D-workflow and simulation capabilities. Since 2023, Xiilab has been successfully leading digital twin construction projects for global companies. Finally, Xiilab will introduce its GPU efficiency enhancement solution 'astrago' at GTC. Equipped with AI training time prediction technology and AI model management capabilities, 'astrago' is designed to optimize GPU utilization. It predicts the usage time of GPUs and combines AI models suitable for specific services, which can maximize GPU efficiency. Users can significantly reduce the costly expenses associated with GPU usage.分析記事 • Mar 01We're Not Very Worried About XIIlabLtd's (KOSDAQ:189330) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...New Risk • Nov 12New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2022 fiscal period end). Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 32% over the past year. Minor Risk Market cap is less than US$100m (₩69.5b market cap, or US$52.7m).New Risk • Jul 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 32% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (₩80.3b market cap, or US$62.8m).Is New 90 Day High Low • Feb 26New 90-day low: ₩36,750The company is down 8.0% from its price of ₩40,000 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Software industry, which is up 9.0% over the same period.お知らせ • Feb 25XIIlab Co.,Ltd, Annual General Meeting, Mar 25, 2021XIIlab Co.,Ltd, Annual General Meeting, Mar 25, 2021, at 10:00 Korea Standard Time.Is New 90 Day High Low • Jan 19New 90-day high: ₩72,000The company is up 125% from its price of ₩32,050 on 21 October 2020. The South Korean market is up 26% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is up 10.0% over the same period.Is New 90 Day High Low • Dec 22New 90-day high: ₩43,700The company is up 36% from its price of ₩32,200 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is up 9.0% over the same period.Is New 90 Day High Low • Nov 27New 90-day high: ₩40,000The company is up 56% from its price of ₩25,600 on 28 August 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is up 3.0% over the same period.お知らせ • Jul 17XIIlab Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 799.94712 million.XIIlab Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 799.94712 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 50,122 Price\Range: KRW 15960 Transaction Features: Subsequent Direct Listing収支内訳XIIlabLtd の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A189330 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Dec 2510,272-3,1192,9782,38530 Sep 259,194-2,9232,6392,08330 Jun 257,956-3,4732,6022,52431 Mar 257,588-4,1102,7322,93231 Dec 249,093-5,1873,0733,20730 Sep 247,824-6,7523,3643,79230 Jun 245,707-7,0673,1783,94431 Mar 245,696-6,8233,0713,91231 Dec 233,663-6,4592,8053,90130 Sep 235,257-5,6542,5513,51430 Jun 239,238-5,1432,8072,86331 Mar 239,418-4,7642,7622,47731 Dec 229,897-4,5452,7262,25031 Dec 215,778-2,1361,7771,352質の高い収益: A189330は現在利益が出ていません。利益率の向上: A189330は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A189330は利益を出していないが、過去 5 年間で年間1.3%の割合で損失を削減してきた。成長の加速: A189330の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: A189330は利益が出ていないため、過去 1 年間の収益成長をSoftware業界 ( 3.6% ) と比較することは困難です。株主資本利益率高いROE: A189330は現在利益が出ていないため、自己資本利益率 ( -12.41% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YSoftware 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/18 07:48終値2026/05/15 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋XIIlab Co.,Ltd 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Jongsun ParkEugene Investment & Securities Co Ltd.
お知らせ • May 15XIIlab Co.,Ltd to Report Q1, 2026 Results on May 28, 2026XIIlab Co.,Ltd announced that they will report Q1, 2026 results at 2:00 PM, Korea Standard Time on May 28, 2026
Reported Earnings • Mar 20Full year 2024 earnings released: ₩851 loss per share (vs ₩1,063 loss in FY 2023)Full year 2024 results: ₩851 loss per share (improved from ₩1,063 loss in FY 2023). Revenue: ₩9.09b (up 148% from FY 2023). Net loss: ₩5.19b (loss narrowed 20% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Aug 17Second quarter 2024 earnings released: ₩307 loss per share (vs ₩268 loss in 2Q 2023)Second quarter 2024 results: ₩307 loss per share (further deteriorated from ₩268 loss in 2Q 2023). Revenue: ₩348.2m (up 3.2% from 2Q 2023). Net loss: ₩1.87b (loss widened 15% from 2Q 2023).
Reported Earnings • Mar 22Full year 2023 earnings released: ₩1,063 loss per share (vs ₩754 loss in FY 2022)Full year 2023 results: ₩1,063 loss per share (further deteriorated from ₩754 loss in FY 2022). Revenue: ₩3.66b (down 63% from FY 2022). Net loss: ₩6.46b (loss widened 42% from FY 2022).
お知らせ • May 15XIIlab Co.,Ltd to Report Q1, 2026 Results on May 28, 2026XIIlab Co.,Ltd announced that they will report Q1, 2026 results at 2:00 PM, Korea Standard Time on May 28, 2026
New Risk • Apr 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩64.6b market cap, or US$43.9m).
分析記事 • Apr 18We Think XIIlabLtd (KOSDAQ:189330) Can Easily Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
お知らせ • Feb 13XIIlab Co.,Ltd, Annual General Meeting, Mar 30, 2026XIIlab Co.,Ltd, Annual General Meeting, Mar 30, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 513, yeongdong-daero, gangnam-gu, seoul South Korea
分析記事 • Jan 02Here's Why We're Not At All Concerned With XIIlabLtd's (KOSDAQ:189330) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
New Risk • Aug 30New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 54% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 9.4% per year over the past 5 years. Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩48.4b market cap, or US$34.9m).
お知らせ • Aug 16XIIlab Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 36.772394 billion.XIIlab Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 36.772394 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,050,068 Price\Range: KRW 5800 Discount Per Security: KRW 104.4 Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,290,000 Price\Range: KRW 5800 Discount Per Security: KRW 104.4 Transaction Features: Rights Offering
New Risk • Jul 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩49.2b market cap, or US$36.4m).
New Risk • May 22New major risk - Revenue and earnings growthEarnings have declined by 17% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩40.7b market cap, or US$29.5m).
お知らせ • May 15XIIlab Co.,Ltd has filed a Follow-on Equity Offering in the amount of KRW 17.8647 billion.XIIlab Co.,Ltd has filed a Follow-on Equity Offering in the amount of KRW 17.8647 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,290,000 Price\Range: KRW 5430 Discount Per Security: KRW 97.74 Transaction Features: Rights Offering
Reported Earnings • Mar 20Full year 2024 earnings released: ₩851 loss per share (vs ₩1,063 loss in FY 2023)Full year 2024 results: ₩851 loss per share (improved from ₩1,063 loss in FY 2023). Revenue: ₩9.09b (up 148% from FY 2023). Net loss: ₩5.19b (loss narrowed 20% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 25XIIlab Co.,Ltd, Annual General Meeting, Mar 26, 2025XIIlab Co.,Ltd, Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 513, yeongdong-daero, gangnam-gu, seoul South Korea
分析記事 • Dec 05We Think XIIlabLtd (KOSDAQ:189330) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Reported Earnings • Aug 17Second quarter 2024 earnings released: ₩307 loss per share (vs ₩268 loss in 2Q 2023)Second quarter 2024 results: ₩307 loss per share (further deteriorated from ₩268 loss in 2Q 2023). Revenue: ₩348.2m (up 3.2% from 2Q 2023). Net loss: ₩1.87b (loss widened 15% from 2Q 2023).
分析記事 • Jul 26Is XIIlabLtd (KOSDAQ:189330) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Reported Earnings • Mar 22Full year 2023 earnings released: ₩1,063 loss per share (vs ₩754 loss in FY 2022)Full year 2023 results: ₩1,063 loss per share (further deteriorated from ₩754 loss in FY 2022). Revenue: ₩3.66b (down 63% from FY 2022). Net loss: ₩6.46b (loss widened 42% from FY 2022).
お知らせ • Mar 20Xiilab Unveils Cutting-Edge AI Technologies At NVIDIA GTCXiilab announced its participation in the global AI conference, NVIDIA GTC, held in San Jose, California, USA, and online from March 18th to 21st, 2024. Xiilab plans to showcase its AI technology at GTC through three main products: AI video analysis service ('VidiGo'), synthetic data generation solution ('X-GEN'), and GPU orchestration solution. The first product, 'VidiGo,' is a cloud-based AI video analysis service that accurately summarizes the core contents of a video without watching it. It can also quickly search for desired video scenes. Users can easily make a database of characters, objects, and dialogues in the video, which significantly improves work efficiency in the media industry. The second product, 'X-GEN,' is a solution for generating synthetic data for AI model training. Especially in areas like disaster response or defense, there is a shortage of data for AI training. X-GEN can provide synthetic data which can replace real data in such rare conditions, even maximizing AI training performance. Xiilab has been applying 'X-GEN' in the digital twin field using the NVIDIA Omniverse. platform, which provides 3D-workflow and simulation capabilities. Since 2023, Xiilab has been successfully leading digital twin construction projects for global companies. Finally, Xiilab will introduce its GPU efficiency enhancement solution 'astrago' at GTC. Equipped with AI training time prediction technology and AI model management capabilities, 'astrago' is designed to optimize GPU utilization. It predicts the usage time of GPUs and combines AI models suitable for specific services, which can maximize GPU efficiency. Users can significantly reduce the costly expenses associated with GPU usage.
分析記事 • Mar 01We're Not Very Worried About XIIlabLtd's (KOSDAQ:189330) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
New Risk • Nov 12New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2022 fiscal period end). Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 32% over the past year. Minor Risk Market cap is less than US$100m (₩69.5b market cap, or US$52.7m).
New Risk • Jul 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 32% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (₩80.3b market cap, or US$62.8m).
Is New 90 Day High Low • Feb 26New 90-day low: ₩36,750The company is down 8.0% from its price of ₩40,000 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Software industry, which is up 9.0% over the same period.
お知らせ • Feb 25XIIlab Co.,Ltd, Annual General Meeting, Mar 25, 2021XIIlab Co.,Ltd, Annual General Meeting, Mar 25, 2021, at 10:00 Korea Standard Time.
Is New 90 Day High Low • Jan 19New 90-day high: ₩72,000The company is up 125% from its price of ₩32,050 on 21 October 2020. The South Korean market is up 26% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Dec 22New 90-day high: ₩43,700The company is up 36% from its price of ₩32,200 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Nov 27New 90-day high: ₩40,000The company is up 56% from its price of ₩25,600 on 28 August 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is up 3.0% over the same period.
お知らせ • Jul 17XIIlab Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 799.94712 million.XIIlab Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 799.94712 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 50,122 Price\Range: KRW 15960 Transaction Features: Subsequent Direct Listing